LMLiberato Marzullo

Liberato Marzullo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liberato Marzullo has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases

    by Anna Donniacuo, Arianna Mauro, Chiara Cardamone, Anna Basile, Paola Manzo, Jelena Dimitrov, Anna Lisa Cammarota, Liberato Marzullo, Massimo Triggiani, Maria Caterina Turco, et al.

    Autoimmune diseases are characterized by dysregulated adaptive immune responses leading to chronic inflammation and tissue damage. Cytokines and growth factors play central roles in modulating immune regulation, inflammation, and tissue repair, thereby representing critical biomarkers for the enhancement of diagnosis, prognosis, and therapeutic monitoring. This review provides a comprehensive overview of pro-inflammatory and anti-inflammatory cytokines, as well as growth factors, emphasizing their pathogenic roles and clinical relevance across various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and connective tissue diseases such as systemic sclerosis, Sjögren’s syndrome, and systemic lupus erythematosus. Key pro-inflammatory cytokines—such as TNF-α, IL-1β, IL-6, IL-17, and IFN-γ—are examined regarding their contributions to disease progression and activity, alongside anti-inflammatory cytokines like IL-10 and IL-4, which regulate immune tolerance and inflammation resolution. Growth factors, such as TGF-β, are analyzed for their dual roles in immune modulation, fibrosis, and tissue remodeling. Cytokine signature profiles employed as diagnostic tools are discussed, together with the need for assay standardization. Advances in multiplex and omics technologies facilitating biomarker discovery are also reviewed. Finally, current and emerging therapeutic strategies targeting cytokines and growth factors, such as anti-TNF agents, IL inhibitors, anti-interferon therapies, and JAK/STAT pathway blockers, are explored.


  • Open Access

    Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases

    by Anna Donniacuo, Arianna Mauro, Chiara Cardamone, Anna Basile, Paola Manzo, Jelena Dimitrov, Anna Lisa Cammarota, Liberato Marzullo, Massimo Triggiani, Maria Caterina Turco, et al.

    Autoimmune diseases are characterized by dysregulated adaptive immune responses leading to chronic inflammation and tissue damage. Cytokines and growth factors play central roles in modulating immune regulation, inflammation, and tissue repair, thereby representing critical biomarkers for the enhancement of diagnosis, prognosis, and therapeutic monitoring. This review provides a comprehensive overview of pro-inflammatory and anti-inflammatory cytokines, as well as growth factors, emphasizing their pathogenic roles and clinical relevance across various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and connective tissue diseases such as systemic sclerosis, Sjögren’s syndrome, and systemic lupus erythematosus. Key pro-inflammatory cytokines—such as TNF-α, IL-1β, IL-6, IL-17, and IFN-γ—are examined regarding their contributions to disease progression and activity, alongside anti-inflammatory cytokines like IL-10 and IL-4, which regulate immune tolerance and inflammation resolution. Growth factors, such as TGF-β, are analyzed for their dual roles in immune modulation, fibrosis, and tissue remodeling. Cytokine signature profiles employed as diagnostic tools are discussed, together with the need for assay standardization. Advances in multiplex and omics technologies facilitating biomarker discovery are also reviewed. Finally, current and emerging therapeutic strategies targeting cytokines and growth factors, such as anti-TNF agents, IL inhibitors, anti-interferon therapies, and JAK/STAT pathway blockers, are explored.


  • Open Access

    BAG3 Positivity as Prognostic Marker in Head and Neck Squamous Cell Carcinoma

    by Pietro De Luca, Francesco Antonio Salzano, Angelo Camaioni, Leopoldo Costarelli, Raul Pellini, Gerardo Petruzzi, Renato Covello, Luigi Vittori, Filippo Ricciardiello, Giuseppe Ricciardiello, et al.

    Background: Head and neck squamous cell carcinoma (HNSCC) exhibit considerable heterogeneity, complicating the prediction of disease progression and treatment response. Consequently, researchers are actively investigating reliable biomarkers to forecast disease trajectories and inform therapeutic decisions. This study examines the role of BAG3, a protein involved in cell survival and stress response, as a potential predictive marker in HNSCC. The objective is to analyze BAG3 expression across various HNSCC types and correlate it with disease-free survival (DFS), aiming to elucidate the influence of BAG3 positivity on cancer progression. Methods: A multi-institutional retrospective study was conducted by analyzing BAG3 expression by immunohistochemistry in 104 tissue samples from patients with head and neck squamous cell carcinoma (HNSCC). The data were then correlated with DFS to assess the impact of BAG3 positivity on prognosis. Results: Immunohistochemical analysis of primary tumor samples collected from therapy-naive patients showed that BAG3 positivity was widespread across different head and neck cancer sites, with no significant correlation to sex, smoking status, HPV infection, tumor location, grade, or TNM parameters. However, BAG3 high positive patients had shorter DFS (median 23.2 months) compared to BAG3-negative patients (median 31.3 months). Cox analysis revealed that BAG3 high expression by IHC was associated with a more than 3-fold increased risk of disease recurrence. Conclusions: This study is the first to explore BAG3 as a biomarker for HNSCC recurrence. While preliminary findings suggest a link between BAG3 positivity and increased recurrence risk, further research is needed to validate these results. Prospective studies could help establish BAG3’s prognostic value and potentially lead to more personalized treatment approaches for HNSCC.


  • Open Access

    Tuning the B-CLL microenvironment: evidence for BAG3 protein- mediated regulation of stromal fibroblasts activity

    by Anna Basile, Valentina Giudice, Laura Mettivier, Antonia Falco, Anna Lisa Cammarota, Angela D’aRdia, Carmine Selleri, Margot De Marco, Nicola De Maio, Maria Caterina Turco, et al.

    The Bcl2-associated athanogene-3 (BAG3) protein, a critical regulator of cellular survival, has been identified as a potential therapeutic target in various malignancies. This study investigates the role of BAG3 within stromal fibroblasts and its interaction with B-cell chronic lymphocytic leukemia (B-CLL) cells. Previous research demonstrated that BAG3 maintains the active state of pancreatic stellate cells (PSCs) and aids pancreatic ductal adenocarcinoma (PDAC) spread via cytokine release. To explore BAG3’s role in bone marrow-derived stromal fibroblasts, BAG3 was silenced in HS-5 cells using siRNA. In co-culture experiments with PBMCs from B-CLL patients, BAG3 silencing in HS-5 cells increased apoptosis and decreased phosphorylation of BTK, AKT, and ERK in B-CLL cells, thus disrupting their pro-survival key signaling pathways. The observation of fibroblast-activated protein (FAP) positive cells in infiltrated bone marrow specimens co-expressing BAG3 further support the involvement of the protein in fibroblast-mediated tumor survival. Additionally, BAG3 appears to support B-CLL survival by modulating cytokine networks, including IL-10 and CXCL12, which are essential for leukemic cell survival and proliferation. A robust correlation between BAG3 expression and the levels of CXCL12 and IL-10 was observed in both co-cultures and patient specimens. These findings point out the need for a more in-depth comprehension of the intricate network of interactions within the tumor microenvironment and provide valuable insights for the selection of new potential therapeutic targets in the medical treatment of CLL.


  • Open Access

    Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment

    by Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D’angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati

    Pancreatic Ductal Adenocarcinoma (PDAC) is a ravaging disease with a poor prognosis, requiring a more detailed understanding of its biology to foster the development of effective therapies. The unsatisfactory results of treatments targeting cell proliferation and its related mechanisms suggest a shift in focus towards the inflammatory tumor microenvironment (TME). Here, we discuss the role of cancer-secreted proteins in the complex TME tumor-stroma crosstalk, shedding lights on druggable molecular targets for the development of innovative, safer and more efficient therapeutic strategies.


  • Open Access

    Pancreatic Cancer- Secreted Proteins: Targeting Their Functions in Tumor Microenvironment

    by Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D'Angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati

    Pancreatic ductal adenocarcinoma (PDAC) is a ravaging disease whose poor prognosis requires a more detailed understanding of its biology to foster the development of effective therapies. The unsatisfactory results of treatments targeting cell proliferation and its related mechanisms suggested to rather focus on the inflammatory tumor microenvironment (TME). Here, we discuss the role of cancer secreted proteins in the complex TME tumor-stroma crosstalk, to sched lights on druggable molecular targets for the development of innovative, safer and more efficient therapeutic strategies.

  • Open Access

    The Continuous Adaptive Challenge Played by Arboviruses: An In Silico Approach to Identify a Possible Interplay between Conserved Viral RNA Sequences and Host RNA Binding Proteins (RBPs)

    by Massimiliano Chetta, Anna Lisa Cammarota, Margot De Marco, Nenad Bukvic, Liberato Marzullo, Alessandra Rosati

    Climate change and globalization have raised the risk of vector-borne disease (VBD) introduction and spread in various European nations in recent years. In Italy, viruses carried by tropical vectors have been shown to cause viral encephalitis, one of the symptoms of arboviruses, a spectrum of viral disorders spread by arthropods such as mosquitoes and ticks. Arboviruses are currently causing alarm and attention, and the World Health Organization (WHO) has released recommendations to adopt essential measures, particularly during the hot season, to restrict the spreading of the infectious agents among breeding stocks. In this scenario, rapid analysis systems are required, because they can quickly provide information on potential virus–host interactions, the evolution of the infection, and the onset of disabling clinical symptoms, or serious illnesses. Such systems include bioinformatics approaches integrated with molecular evaluation. Viruses have co-evolved different strategies to transcribe their own genetic material, by changing the host’s transcriptional machinery, even in short periods of time. The introduction of genetic alterations, particularly in RNA viruses, results in a continuous adaptive fight against the host’s immune system. We propose an in silico pipeline method for performing a comprehensive motif analysis (including motif discovery) on entire genome sequences to uncover viral sequences that may interact with host RNA binding proteins (RBPs) by interrogating the database of known RNA binding proteins, which play important roles in RNA metabolism and biological processes. Indeed, viral RNA sequences, able to bind host RBPs, may compete with cellular RNAs, altering important metabolic processes. Our findings suggest that the proposed in silico approach could be a useful and promising tool to investigate the complex and multiform clinical manifestations of viral encephalitis, and possibly identify altered metabolic pathways as targets of pharmacological treatments and innovative therapeutic protocols.


  • Open Access

    The Continuous Adaptive Challenge Played by Arboviruses: An In Silico Approach to Define Relevant Molecular Interactions with the Host

    by Massimiliano Chetta, Anna Lisa Cammarota, Margot De Marco, Nenad Bukvic, Liberato Marzullo, Alessandra Rosati

    Climate change and globalization have raised the risk of vector-borne disease (VBD) introduction and spread in various European nations in recent years. In Italy, viruses carried by tropical vectors have been shown to cause viral encephalitis, one of the symptoms of arbovirosis, a spectrum of viral disorders spread by arthropods such as mosquitoes and ticks. Arbovirosis are currently causing alarm and attention, and the World Health Organization (WHO) has released recommendations to adopt essential measures, particularly during the hot season, to restrict the spreading of the infectious agents among breeding stocks. In this scenario, rapid analysis systems are required, because they can quickly provide information on potential virus-host interactions, the evolution of the infection, and the onset of disabling clinical symptoms, or serious illnesses. Such systems include bioinformatics approaches integrated with molecular evaluation. Viruses have co-evolved different strategies to transcribe their own genetic material, by changing the host's transcriptional machinery, even in short periods of time. The introduction of genetic alterations, particularly in RNA viruses, results in a continuous adaptive fight against the host's immune system. We suggest an in silico pipeline method to unravel viral sequences that may interact with host RNA binding proteins (RBPs), which play important roles in RNA metabolism and its several related biological processes. Indeed, viral RNA sequences, able to bind host RBPs may compete with cellular RNAs, altering important metabolic processes. Our findings suggest that the proposed in silico approach, could be a useful and promising tool to investigate the complex and multiform clinical manifestations of viral encephalitis, and possibly identify altered metabolic pathways as targets of pharmacological treatments and innovative therapeutic protocols.

  • Open Access

    Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma

    by Matthew A. Firpo, Kenneth M. Boucher, Josh Bleicher, Gayatri D. Khanderao, Alessandra Rosati, Katherine E. Poruk, Sama Kamal, Liberato Marzullo, Margot De Marco, Antonia Falco, et al.

    PURPOSE: We determined whether a large, multianalyte panel of circulating biomarkers can improve detection of early-stage pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS: We defined a biologically relevant subspace of blood analytes on the basis of previous identification in premalignant lesions or early-stage PDAC and evaluated each in pilot studies. The 31 analytes that met minimum diagnostic accuracy were measured in serum of 837 subjects (461 healthy, 194 benign pancreatic disease, and 182 early-stage PDAC). We used machine learning to develop classification algorithms using the relationship between subjects on the basis of their changes across the predictors. Model performance was subsequently evaluated in an independent validation data set from 186 additional subjects. RESULTS: A classification model was trained on 669 subjects (358 healthy, 159 benign, and 152 early-stage PDAC). Model evaluation on a hold-out test set of 168 subjects (103 healthy, 35 benign, and 30 early-stage PDAC) yielded an area under the receiver operating characteristic curve (AUC) of 0.920 for classification of PDAC from non-PDAC (benign and healthy controls) and an AUC of 0.944 for PDAC versus healthy controls. The algorithm was then validated in 146 subsequent cases presenting with pancreatic disease (73 benign pancreatic disease and 73 early- and late-stage PDAC cases) and 40 healthy control subjects. The validation set yielded an AUC of 0.919 for classification of PDAC from non-PDAC and an AUC of 0.925 for PDAC versus healthy controls. CONCLUSION: Individually weak serum biomarkers can be combined into a strong classification algorithm to develop a blood test to identify patients who may benefit from further testing.


  • Open Access

    BAG3 induces α‐SMA expression in human fibroblasts and its over‐expression correlates with poorer survival in fibrotic cancer patients

    by Margot De Marco, Nicoletta Del Papa, Francesca Reppucci, Vittoria Iorio, Anna Basile, Antonia Falco, Roberta Iaccarino, Sergio Brongo, Francesco De Caro, Mario Capunzo, et al.

    Hypoxia and angiogenesis in solid tumors are often strictly linked to the development of fibrotic tissues, a detrimental event that compromises the antitumor immunity. As a consequence, tumor aggressiveness and poor patient prognosis relate to higher incidence of tissue fibrosis and stromal stiffness. The molecular pathways through which normal fibroblasts are converted in cancer‐associated fibroblasts (CAFs) have a central role in the onset of fibrosis in tumor stroma, thus emerging as a strategic target of novel therapeutic approaches for cancer disease. Several studies addressed the role of BAG3 in sustaining growth and survival of cancer cell and also shed light on the different mechanisms in which the intracellular protein is involved. More recently, new pieces of evidence revealed a pivotal role of extracellular BAG3 in pro‐tumor cell signaling in the tumor microenvironment, as well as its involvement in the development of fibrosis in tumor tissues. Here we report further data showing the presence of the BAG3 receptor (Interferon‐induced transmembrane protein [IFITM]‐2) on the plasma membrane of normal dermal fibroblasts and the activity of BAG3 as a factor able to induce the expression of α‐smooth muscle actin and the phosphorylation of AKT and focal adhesion kinase, that sustain CAF functions in tumor microenvironment. Furthermore, in agreement with these findings, bag3 gene expression has been analyzed by high throughput RNA sequencing databases from patients‐derived xenografts. A strong correlation between bag3 gene expression and patients' survival was found in several types of fibrotic tumors. The results obtained provide encouraging data that identify BAG3 as a promising therapeutic target to counteract fibrosis in tumors.